Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Marijuana and multiple sclerosis.

Goodin D.

Lancet Neurol. 2004 Feb;3(2):79-80. Review. No abstract available.

PMID:
14746994
2.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
3.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M.

Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. Review. German.

PMID:
16052440
4.

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.

Voth EA, Schwartz RH.

Ann Intern Med. 1997 May 15;126(10):791-8. Review.

PMID:
9148653
5.
6.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
7.

What place for ▾ cannabis extract in MS?

[No authors listed]

Drug Ther Bull. 2012 Dec;50(12):141-4. doi: 10.1136/dtb.2012.11.0150. Review.

PMID:
23241565
8.

Are cannabinoids effective in multiple sclerosis?

Meza R, Peña J, García K, Corsi O, Rada G.

Medwave. 2017 Mar 10;17(Suppl1):e6865. doi: 10.5867/medwave.2017.6865. Review. Spanish, English.

PMID:
28306712
9.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Boggild M, Young C.

Cochrane Database Syst Rev. 2001;(4):CD001332. Review. Update in: Cochrane Database Syst Rev. 2003;(4):CD001332.

PMID:
11687107
10.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Young CA, Boggild M.

Cochrane Database Syst Rev. 2000;(4):CD001332. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD001332.

PMID:
11034714
11.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Boggild M, Young C.

Cochrane Database Syst Rev. 2003;(4):CD001332. Review.

PMID:
14583932
12.

[Multiple sclerosis and botulinum toxin].

Lamotte D, Thoumie P.

Ann Readapt Med Phys. 2003 Jul;46(6):299-302. Review. French.

PMID:
12928133
13.

Drug treatment of multiple sclerosis.

Rudick RA, Schiffer RB, Herndon RM.

Semin Neurol. 1987 Jun;7(2):150-9. Review. No abstract available.

PMID:
2845549
14.

Current pharmacologic treatment of multiple sclerosis symptoms.

Andersson PB, Goodkin DE.

West J Med. 1996 Nov;165(5):313-7. Review.

15.

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP.

Nervenarzt. 2004 Oct;75(10):1022-6. Review. German.

PMID:
15156287
16.

[Non-medicinal treatments of spasticity in multiple sclerosis].

Mailhan L, Papeix C.

Rev Neurol (Paris). 2012 Apr;168 Suppl 3:S57-61. doi: 10.1016/S0035-3787(12)70048-6. Review. French.

PMID:
22721366
17.

Use of botulinum toxin type A and type B for spasticity in upper and lower limbs.

Bell KR, Williams F.

Phys Med Rehabil Clin N Am. 2003 Nov;14(4):821-35. Review.

PMID:
14580040
18.

Cannabis-based medicines in multiple sclerosis--a review of clinical studies.

Rog DJ.

Immunobiology. 2010 Aug;215(8):658-72. doi: 10.1016/j.imbio.2010.03.009. Epub 2010 Apr 7. Review.

PMID:
20541836
19.

Treatment of spasticity with botulinum toxin.

O'Brien CF.

Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S182-90. Review.

PMID:
12569967
20.

[Spasticity in multiple sclerosis].

Pappalardo A, Patti F, Reggio A, Guglielmino A, Mangiameli S.

Clin Ter. 2004 Apr;155(4):135-8. Review. Italian.

PMID:
15354762

Supplemental Content

Support Center